JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zenz, T.
Right arrow Articles by Bunjes, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zenz, T.
Right arrow Articles by Bunjes, D.

Bone Marrow Transplantation Nephropathy after an Intensified Conditioning Regimen with Radioimmunotherapy and Allogeneic Stem Cell Transplantation

Thorsten Zenz, MD1, Richard F. Schlenk, MD1, Gerhard Glatting, PhD2, Bernd Neumaier, PhD2, Norbert Blumstein, MD2, Inga Buchmann, MD2, Stephanie von Harsdorf, MD1, Mark Ringhoffer, MD1, Markus Wiesneth, MD3, Frieder Keller, MD4, Jörg Kotzerke, MD2, Erwin Röttinger, MD5, Stephan Stilgenbauer, MD1, Hartmut Döhner, MD1, Sven N. Reske, MD2 and Donald Bunjes, MD1

1 Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; 2 Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany; 3 Department of Transfusion Medicine, University Hospital Ulm, Ulm, Germany; 4 Department of Internal Medicine II, University Hospital Ulm, Ulm, Germany; and 5 Department of Radiation Therapy, University Hospital Ulm, Ulm, Germany


Figure 1
View larger version (70K):

[in a new window]
  		FIGURE 1.  Representative planar {gamma}-camera images of patients receiving 188Re and 111In (left, mirrored anterior; right, posterior). p.i. = after injection.

 

Figure 2
View larger version (15K):

[in a new window]
  		FIGURE 2.  Creatinine values at different times for patients with BMT nephropathy. a = initiation of hemodialysis.

 

Figure 3
View larger version (22K):

[in a new window]
  		FIGURE 3.  (A) Competitive risk analysis for patients receiving 188Re and 90Y (P = 0.27). (B) Competitive risk analysis for patients with and without TBI (P = 0.12).

 

Figure 4
View larger version (9K):

[in a new window]
  		FIGURE 4.  Renal dose as calculated by dosimetry for patients receiving 188Re vs. 90Y (6.9 ± 0.3 Gy vs. 4.4 ± 0.5 Gy; t test, P < 0.0001).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.